Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3217]

European Commission grants approval to blinatumomab for ALL

European Commission grants approval to blinatumomab for ALL

$EHA 23: Quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML$

EHA 23: Quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML

EHA 23: JAK inhibitors associated with aggressive lymphoma

EHA 23: JAK inhibitors associated with aggressive lymphoma

Researchers map the genome of testicular cancer

Researchers map the genome of testicular cancer

Modern blood cancer treatments require new approach for monitoring, reporting side effects

Modern blood cancer treatments require new approach for monitoring, reporting side effects

Drug that targets metabolic vulnerability and impairs cancer cell growth and survival ID'd

Drug that targets metabolic vulnerability and impairs cancer cell growth and survival ID'd

New epigenetic drug against Mantle Cell Lymphoma

New epigenetic drug against Mantle Cell Lymphoma

FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy

FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy

Rigorous study finds widely used treatment for infection fails young cancer patients

Rigorous study finds widely used treatment for infection fails young cancer patients

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions

More from ecancer